SFRP1 and neoplasm: In accordance with a previous work from Bernemann et al., we found that, in the public dataset, TNBC patients who had a complete pathological response to chemotherapy had a higher SFRP1 expression than non-responder, suggesting that SFRP1 could be a potential tumor suppressor in TNBC, as well as a good prognostic marker [43].